Instil Bio (TIL) Income from Continuing Operations (2020 - 2026)
Instil Bio (TIL) posted quarterly Income from Continuing Operations of 7884000.0 for Q1 2026, up 74.14% year-over-year from 4527441.13 in Q1 2025, and up 24.03% quarter-over-quarter from 10378000.0 in Q4 2025.
Instil Bio (TIL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Instil Bio's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 7884000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 74.14% year-over-year to 7884000.0; the TTM figure through Mar 2026 stood at 57951000.0 (up 29.46% YoY), while the FY2025 annual figure was 80552000.0, up 61.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 7884000.0, up from 10378000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7884000.0 in Q1 2026, with the low at 67432000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 23978000.0 (2025), against an average of 31955529.41.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 133.99% in 2022, then jumped 76.0% in 2023.
- Instil Bio's Income from Continuing Operations stood at 53844000.0 in 2022, then surged by 76.0% to 12925000.0 in 2023, then dropped by 4.22% to 13471000.0 in 2024, then increased by 22.96% to 10378000.0 in 2025, then gained by 24.03% to 7884000.0 in 2026.
- Business Quant data shows TIL's Income from Continuing Operations at 7884000.0 in Q1 2026, 10378000.0 in Q4 2025, and 15711000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | -6.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Mn |
| Mar 31, 2026 | -7.88 Mn |
| Dec 31, 2025 | -10.38 Mn |
| Sep 30, 2025 | -15.71 Mn |
| Jun 30, 2025 | -23.98 Mn |
| Mar 31, 2025 | -30.49 Mn |
| Dec 31, 2024 | -13.47 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -14.22 Mn |
| Mar 31, 2024 | -23.87 Mn |
| Dec 31, 2023 | -12.93 Mn |
| Sep 30, 2023 | -67.43 Mn |
| Jun 30, 2023 | -18.66 Mn |
| Mar 31, 2023 | -57.07 Mn |
| Dec 31, 2022 | -53.84 Mn |
| Sep 30, 2022 | -56.22 Mn |
| Jun 30, 2022 | -58.99 Mn |
| Mar 31, 2022 | -54.12 Mn |
| Dec 31, 2021 | -55.35 Mn |
| Sep 30, 2021 | -43.01 Mn |